univers coverag
calendar event
medacorp puls call gear aao surgeon perspect
robot total joint trend new product area estimate
medic meet bmt tandem meet american societi blood marrow
transplant asbmt center intern blood marrow transplant research
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
hiv survey rapid adopt biktarvi challeng outlook
bottom line hiv treatment market becom categori domin gilead
mp gsk mp categori central valuat gilead import
valuat gsk gilead newli introduc biktarvi gsk advanc dolutegravir
base combin potenti disrupt current treatment pattern trend
categori assess impact introduct recent complet medacorp survey
us hiv treatment specialist survey found impress posit sentiment gild biktarvi
bictegravir emtricitabin tenofovir alafenamid fixed-dos combin seem like put
sustain pressur gsk lead integras inhibitor tivicay well cannib gilead
combin compon product survey respond estim penetr integras
inhibitor estim increas patient gsk/viiv
dolutegravir-bas regimen tivicay/triumeq expect declin integras inhibitor
regimen two year biktarvi share estim reach integras
inhibitor market increas gild share respond see place viiv two drug regimen
patient stabl integras inhibitor regimen survey also suggest tivicay
novemb label updat cite hepatotox risk could neg affect use dolutegravir-
base regimen medacorp specialist either plan alreadi chang
prescrib habit survey respond suggest gilead commerci execut support
biktarvi launch effect beyond immedi term disrupt event
categori includ introduct gener version gilead viread year gener version
truvada atripla complera descovi late base survey updat market
compani model hiv product incorpor faster deeper share gain biktarvi
greater eros tivicay well cannib gilead exist product longer term
includ rapid gener eros gilead legaci combin product gener entri littl
secondari effect avail adopt remain brand product
eu specialist confirm like rapid adopt biktarvi europ limit role doublet
gild biktarvi major headwind viiv increment cautiou gsk near-term cut
tivicay/triumeq estim gsk valuat two-drug pipelin strategi key viiv futur growth
ep penc ep estim reflect core ep excl extraordinari item reflect ifr restat
revenu mm non-gaap ep ex stock option expens
tripl pivot trial short sweet launch feasibl
ep rev disc dcf wacc tg
bottom line vertex announc yesterday market close initi first
four phase tripl combin studi time month ahead prior expect
even importantli trial shorter compani prior pivot studi
cf combin fda agre singl pivot trial high unmet need het-min cf
popul primari efficaci endpoint safeti endpoint
week extend blind follow secondari endpoint follow convers
manag clear first tripl trial enrol quickli believ
regulatori submiss could occur earli half base updat
acceler launch time tripl combin one quarter
previous ad tripl combin revenu het/min popul model
updat chang price target maintain outperform
rate vertex stock
bottom line even announc ema chmp committe medicin product
human use commun posit trend vote rubraca line brca ovarian
cancer treatment set posit news share view line base case
scenario reflect model link think small overhang form share context
neg trend vote op nerlynx scientif advisori group sag meet
request eu chmp applic formal posit chmp opinion rubraca
expect late-march eu approv line treatment set expect importantli
file variat rubraca pend condit approv request approv
larger line mainten set patient independ brca statu base result
clinic trial expect review cycl rubraca like obtain eu approv
line late vs near case scenario maintain op rate
remain posit stock base posit view regard overal opportun parp
inhibitor oncolog rubraca product profil upcom event includ expect us
fda approv line mainten set april pdufa well phase ii interim data
pivot phase ii trial metastat castrate-resist prostat cancer mcrpc
rubraca receiv posit trend vote chmp line treatment set eu approv like
current model pt reflect rubraca eu entri consist today news
bottom line afternoon gwph announc phase ii studi cbdv
cannabidivarin meet primari endpoint drug arm placebo arm
perform similarli recent highlight view cbdv link product
encourag preclin data note readout shot offer investor attract
high upsid downsid opportun result even therefor
disappoint howev note gwph valuat sole driven epidiolex cash
never includ credit cbdv given lack clinic result gener date gw
report cbdv control group show reduct seizur meanwhil
rate advers event higher cbdv versu placebo vs howev magnitud
differ ae rate dissimilar seen prior studi epidiolex profil
seem justifi continu research cbdv diseas area autism gw reiter
commit on-going physician-l studi soon-to-be-initi trial rett syndrom
continu recommend stock basi expect epidiolex approv late june
optim epidiolex launch back strong data high unmet need physician/pati
enthusiasm beat investor expect reiter op gwph
top guidanc consen color need lo
bottom line report revenu ebitda ep beat provid initi ebitda
guidanc line consensu high-end price volum strong
us uk line commentari op recent leerink global health confer
off-set weak length stay lo us uk color need driver
consolid oper expens rel line expect call today estimate
focu fundament bh facil busi includ volum lo price payor mix
clinic staf shortag regulatori scrutini code rate market perform
beat revenu ebitda ep
us ss admiss price strong lo declin sequenti yoy color
need call
uk volum price growth strong overal uk challeng weaker censu larg
lo declin wage pressur due tighten labor market
introduc ebitda guidanc mm line consensu mm
manag host confer call thursday februari estimate dial-in detail
passcod need
dcf sop analysi discount rate termin growth rate
bottom line updat estim follow report financi result
maintain mp rate view compani clinic stage pipelin fairli valu end
consist prior guidanc expect suffici fund run oper
pipelin progress in-lin expect reiter upcom
mileston lentiglobin transfusion-depend beta-thalassemia tdt guid
data european hematolog associ eha meet june
data american societi hematolog meet dec
anticip first regulatori file eu genotyp lentiglobin sickl
cell diseas scd guid data scd develop plan
registr updat initi investigator-l phase studi lentivir gene therapi
target suppress fetal hemoglobin upregul patient scd expect
also guid lenti-d cald cerebr adrenoleukodystrophi starbeam data
next step includ expand studi enrol total patient first file anticip
anti-bcma car-t program multipl myeloma guid on-going phase
studi data plan initi line studi also guid
data next-gen anti-bcma car-t
revenu million
bottom line cotv post modest ep beat strong rca perform off-set
continu issu pca importantli posit side long anticip guidanc
in-lin bracket consensu expect conservat bake potenti
upsid rate cotv outperform
modest adj ebitda ep beat
solid rca growth partial off-set weaker pca perform
rca one-tim perform issu drive previou guid appear resolv
guidanc in-lin
manag host confer call estimate today
bottom line elgx deliv revenue result revenue /ep guidanc consensu also
conjunct earn releas compani also announc ceo john mcdermott
step think afx/weak nellix sale could serv extend overhang
stock least management demonstr progress front beyond
number re-set downward perhap leadership chang could portend
improv execut go forward front still see elgx catalyst growth re-
acceler weight see rush share reiter
mp pt goe vs base ev/sal lower revenue forecast
ceo john mcdermott step year elgx remain role
revenu mm ep adjust item
robot trauma great momentum pt
bottom line result rev/ep outlook -- -both consensu -- -increas
confid compani cusp sustain revenu growth acceler trajectori
compani increasingli begin benefit emerg product cycl robot
 trauma updat model reflect full result sale pre-announce
forecast increas due higher assumpt around compani robot trauma emerg
initi -- -we think step re-invest tax reform yield bigger payoff
out-year vs prior think medacorp feedback continu point high level
interest excelsiusgp think even higher out-year above-consensu estim still bake
conservat result reiter op rate increas pt vs appli
current forward multipl ev/ebitda higher ebitda
think premium multipl vs peer sustain given well-above-avg profit
profil acceler dd sale growth prospect sales/ep upsid potenti
revenue pre-announce ep beat
reiter revenue guidanc y/i assum share gain compani us core spine segment
addit contribut emerg technolog robot trauma on-going contribut
alphatec organ
project revenu growth acceler y/i
even increment invest tap ebitda margin sustain
revenu million
feb c-suit meet rx tour sleeper stock new pt
 methodolog price-to-earnings ep
bottom line came away see sleeper stock post c-suit
meet organ ami smith director ir manag includ cfo brian kane
ceo bruce broussard pharmaci tour cincinnati oh reiter estim rais
pt
tax polici tailwind shot arm top-lin growth margin expans
next year
integr clinic model recent knd acquisit de novo jv build-out
primari care conviva platform tx fl focus captiv pbm oper rejuven hum
broader transform healthcar landscap chang endur strategi
intens consum clinic focu care manag senior
capit deploy could consid larger medicaid target next year support
dual special need plan d-snp growth subject regulatori chang state may mandat
medicaid presenc d-snp growth though organ strategi seem like prioriti
includ tuck-in deal subject anti-trust scrutini
valuat upsid conserv earn estim multipl expans
earn deliv anoth strong guid ahead street
 methodolog sale
bottom line deliv anoth strong quarter out-performance come ahead
expect across key busi highlight strong underli believ
sustain adopt momentum particularli within core omnipod busi expect
share outperform tomorrow reaction strong print re-affirmed commit
oper margin profit even invest direct intern infrastructur us
remain one cleanest execut stori within smid-cap coverag univers deliv
consist beat rais quarter top-lin row sign slow momentum
support view fact manag issu sale guidanc
impli y/i growth well ahead street us even
exclud benefit chang account tie revenu recognit relat
quarter revenu came y/i ahead us y/i
street exceed high end compani guidanc rang
view well posit achiev sale target driven on-going coverag
expans patient fall medicar medicaid local payer -- benefit
factor guidanc continu pipelin progress dash showcas ada june
set launch share gain anima exit pump market
on-going intern momentum transit direct distribut europ
reiter op pt
outlook move higher still conserv intern transit biggest risk seem
appropri handicap guidanc
revenu ep figur includ fa option expens
recap orion trial enrol rapidli regulatori file possibl
discount rate termin growth
bottom line mdco remain focus inclisiran clinic develop hypercholesterolemia
first two studi complet enrol ahead expect nda/
submiss possibl concurr cost-cut measur proce
melinta mlnt nr transact reduc risk sharehold dilut regulatori file
inclisiran reiter op pt
encourag execut drive multipl expans
 methodolog ep
bottom line deliv believ encourag rebound quarter
mute despit acceler organ growth stock trade lower today reaction
lack guidanc rais reiter guidanc impli less robust ramp vs
deliv oper margin fell short vs consensu adjust basi
covidien synergi complet compani launch new cost-
save program expect deliv save next five year
annual wait manag provid color key driver increment
margin expans initi presum analyst day june remain cautiou mdt abil
drive meaning margin expans beyond trade discount
broader med-tech group -- vs group remain sidelin given
consider execut risk drive multipl expans acceler sale growth trajectori
highli lever success execut current upcom new product launch includ
tyrx absorb antibacteri envelop resolut onyx drug elut stent intelli platform spinal cord
stimul pump guardian connect stand-alone sensor increment margin expans
like tougher come larg predic strong execut new product launch
competit headwind continu ramp next month key high growth area
includ dcb tavr db
revenu mm ep
pharmaci servic panel retain share wba/abc deal
trump administr releas rule short term health insur
downward movement stock price creat buy oppt
decent quarter dental rebound pt
recap commerci luxturna hemo updat
discount rate termin growth rate
increas pt takeda collabor stock weak offer oppti
hcit distribut preview posit coordin vbc cautiou
medic suppli devic individu co preview cardio large-cap diversifi
